Sage Journals: Discover world-class research

Abstract

Ruxolitinib is a small molecule JAK-2 inhibitor approved for the treatment of certain myeloproliferative neoplasms. Ruxolitinib-related skin toxicity is extremely rare. We report herein an unusual erythematous skin eruption with necrotic centers involving lower extremities in a patient with primary myelofibrosis treated with ruxolitinib. Awareness of this unusual skin toxicity with ruxolitinib becomes even more important as JAK-2 inhibition might soon find clinical applications in dermatology.

Keywords

JAK-2 inhibitor primary myelofibrosis ruxolitinib side effect skin eruption

Get full access to this article

View all access options for this article.

References

Mughal

Vaddi

Sarlis

et al.

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 2014; 7: 89–101.

Fournier

Cummings

Cannella

et al.

Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib. Dermatol Online J 2014; 20. https://www.ncbi.nlm.nih.gov/pubmed/?term=Fournier+JB%2C+Cummings+F%2C+Cannella+J%2C .

Chatterjee

Rqieh

Greaves

et al.

Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis. Br J Haematol 2015; 169: 307–307.

Del Rosario

Tsai

Dasanu

. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis. J Oncol Pharm Pract 2018; 24: 226–228.

Damsky

King

. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 2017; 76: 736–744.

Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis

Abstract

Keywords

Get full access to this article

References